Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.

Comparative Tolerability of Newer Agents for Insomnia

Zammit, Gary · 2009 · Drug Safety

Abstract

Newer treatment options for insomnia include the non-benzodiazepine hypnotics zolpidem, zolpidem-controlled release, zaleplon, zopiclone, eszopiclone and the melatonin receptor agonist, ramelteon. These compounds are generally well tolerated and present favourable safety profiles in comparison with the older benzodiazepines and barbiturates. Commonly cited impairments of memory formation and decrements in psychomotor performance are related to the mechanism of action of hypnotics, and are both dose- and time-dependent. These effects typically are minimal on the morning following night-time administration. The non-benzodiazepines are associated with some risk for dependence and abuse. However, concerns regarding such risks appear to be greater than warranted by empirical evidence. The appropriate therapeutic use of hypnotics is generally not associated with physiological responses that are commonly thought to lead to dependence, such as tolerance or discontinuation effects. Former substance abusers and psychiatric patients appear to be at greatest risk. The labelling of hypnotics was recently updated to incorporate warnings about very rare, but serious adverse events that have been identified in postmarketing surveillance. These events include anaphylaxis (severe allergic reaction); angio-oedema (severe facial swelling); and complex sleep-related behaviours, which may include sleep-driving, making phone calls and preparing and eating food. This article will review the adverse event profiles of these newer sedative hypnotics, their effects on memory and psychomotor performance, abuse liability concerns and the most recent information about the rare adverse effects that prompted the recent revision to the labelling of drugs in the hypnotic class.

Overview

Integrity signals

Registry

Crossref · 10.2165/11312920-000000000-00000

Cites

126 of 126 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 126 references

Research works printed but not linked: 31

  1. Scharf, 1994 May, J Clin Psychiatry, 55, 192
  2. Roger, 1993 Jan-Feb, Clin Ther, 15, 127
  3. Frattola, 1990, Drugs Exp Clin Res, 16, 371
  4. Scharf, 1991 Feb, J Clin Psychiatry, 52, 77
  5. Isawa, 2000 May, Nihon Shinkei Seishin Yakurigaku Zasshi, 20, 61
  6. Vermeeren, 2002 Mar 15, Sleep, 25, 224
  7. Griffiths, 2005, J Clin Psychiatry, 66, 31
  8. Gieschke, 1994 Nov, Methods Find Exp Clin Pharmacol, 16, 667
  9. Vermeeren, 1995, Acta Ther, 21, 47
  10. Uchiumi, 2000 Aug, Nihon Shinkei Seishin Yakurigaku Zasshi, 20, 123
  11. Tamminen, 1987, Sleep, 10, 63
  12. Ponciano, 1990 Apr, Int Clin Psychopharmacol, 5, 69
  13. Gary, 2004, Sleep, 27, A56
  14. Roth, 2005 Mar 1, Sleep, 28, 303
  15. Wang-Weigand, 2007, Sleep, 30, A244
  16. Hajak, 2007, Sleep, 30, A245
  17. Moldofsky, 1996 Mar, J Rheumatol, 23, 529
  18. Erman, 2007, Sleep, 30, A241
  19. Erman, 2007, Sleep, 30, A241
  20. Krystal, 2006, Sleep, 29, A249
  21. France, 2005, Sleep, 28, A45
  22. France, 2005, Sleep, 28, A45
  23. Nishida, 2005, Sleep, 28, A45
  24. Zammit, 2005, Sleep, 28, A228
  25. Karim, 2004, AAPS J, 6, R6196
  26. Tolbert, 2004, AAPS J, 6, R6195
  27. Karim, 2005, Sleep, 28, A45
  28. Maier, 2004, Sleep, 27, A56
  29. Karim, 2004, Sleep, 27, A53
  30. Karim, 2004, AAPS J, 6, R6197
  31. Najjar, 2007 Oct 15, J Clin Sleep Med, 3, 637, 10.5664/jcsm.26976 · DOI

Cited by

See all 98

Metadata

Authors
Zammit, G.
Affiliations
Clinilabs (United States) (US)
Corresponding author
Zammit, Gary
Venue
Drug Safety
Published
2009-09
Volume
32
Issue
9
Pages
735-748
ISSN
0114-5916 (ISSN-L)
OpenAlex
W2023944666
Cited by
98
References
126
Citations by year
2026: 1 · 2025: 2 · 2023: 7 · 2022: 3 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 3 · 2016: 2 · 2015: 12 · 2014: 7 · 2013: 12 · 2012: 12
FWCI
1.71
Type
journal article
Language
en
Open access
closed
Locations
  • Drug Safety (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
Keywords
insomnia, non-benzodiazepine hypnotics, zolpidem, zaleplon, zopiclone, eszopiclone, ramelteon, melatonin receptor agonists, drug tolerability, adverse drug reactions, memory impairment, psychomotor performance, hypnotic dependence, abuse liability, drug labeling, anaphylaxis, angioedema, benzodiazepines, barbiturates
MeSH terms
Zolpidem, Clinical Trials as Topic, Drug Interactions, Humans, Hypnotics and Sedatives, Indenes, Sleep Initiation and Maintenance Disorders, Memory, Piperazines, Psychomotor Performance, Pyridines, Substance Withdrawal Syndrome, Randomized Controlled Trials as Topic, Substance-Related Disorders, Azabicyclo Compounds

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative Tolerability of Newer Agents for Insomnia. https://app.cochat.ai/papers/10.2165/11312920-000000000-00000
The paper
Zammit, G. (2009). Comparative Tolerability of Newer Agents for Insomnia. Drug Safety. https://doi.org/10.2165/11312920-000000000-00000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.